Breast Cancer Statistics, 2022

Angela N. Giaquinto,Hyuna Sung,Kimberly D. Miller,Joan L. Kramer,Lisa A. Newman,Adair Minihan,Ahmedin Jemal,Rebecca L. Siegel

DOI: https://doi.org/10.3322/caac.21754

2022-10-06

CA A Cancer Journal for Clinicians

Abstract:This article is the American Cancer Society's update on female breast cancer statistics in the United States, including population‐based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010–2019), the rate increased by 0.5% annually, largely driven by localized‐stage and hormone receptor‐positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989–2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016–2020) and two‐fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5‐year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black–White gaps in absolute terms for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative disease (88% vs. 96%), hormone receptor‐negative/human epidermal growth factor receptor 2‐positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high‐quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to provide the latest statistical data on breast cancer in American women, including incidence, mortality, survival rate, and the situation of mammography screening. Specifically, the paper focuses on the following aspects:

1. **Trends in breast cancer incidence**:
- The paper analyzes the changing trends in breast cancer incidence over the past few decades. From 2010 to 2019, the breast cancer incidence increased by 0.5% annually, mainly driven by local - stage and hormone - receptor - positive diseases.

2. **Trends in breast cancer mortality**:
- The paper explores the changing trends in breast cancer mortality. Since reaching its peak in 1989, breast cancer mortality has been steadily declining, but the rate of decline has slowed in recent years. From 2011 to 2020, the mortality rate decreased by 1.3% annually, while in the previous decade (from 2002 to 2011), it decreased by 1.9% annually. Overall, from 1989 to 2020, the mortality rate decreased by 43%, which is equivalent to a reduction of 460,000 breast cancer deaths.

3. **Racial/ethnic differences**:
- The paper pays special attention to the differences in breast cancer incidence and mortality among different racial/ethnic groups. Although the breast cancer incidence among black women is lower than that among white women (127.8 vs. 133.7 per 100,000 people), there are significant differences in breast cancer mortality, with the mortality rate among black women being 40% higher than that among white women (27.6 vs. 19.7 per 100,000 people). This difference is particularly evident among young women, with the mortality rate among black women being twice that among white women (12.1 vs. 6.5 per 100,000 people).

4. **Impact of molecular subtypes and staging**:
- The paper also analyzes the impact of different molecular subtypes and staging on breast cancer survival rate. For example, black women have the lowest 5 - year relative survival rate in each molecular subtype and staging, especially for hormone - receptor - positive/HER2 - negative diseases (88% vs. 96%), hormone - receptor - negative/HER2 - positive diseases (78% vs. 86%), and stage III diseases (64% vs. 77%).

5. **Recommendations for prevention and treatment**:
- The paper proposes suggestions to accelerate the reduction of breast cancer mortality by increasing the accessibility of high - quality screening and treatment, especially by expanding Medicaid nationwide and through the cooperation of community stakeholders, advocacy organizations, and health systems to reduce racial differences.

In summary, this paper aims to comprehensively update and analyze the epidemiological data of breast cancer in American women, emphasize racial/ethnic differences, and put forward specific suggestions for improving breast cancer prevention and treatment.